A clinical study on the treatment of generalized anxiety disorder with the

Phase 1

• Conditions: Generalized anxiety disorder

• Registration Number: ITMCTR2000004129
• Lead Sponsor: West China Hospital, Sichuan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. MEET the diagnostic criteria of GAD in CCMD-3;
2. The age should be 18-75 years old;
3. Hamilton Anxiety Scale (HAMA) score >=14;
4. Patients who receive and adhere to western medicine or acupuncture treatment;
5. Sign the informed consent.

Exclusion Criteria

1. Secondary anxiety of somatic diseases, drug withdrawal reaction, and secondary anxiety of other mental diseases;
2. Pregnant and lactating women with severe cardiopulmonary, liver and kidney dysfunction;
3. History of organic brain disease and serious mental illness;
4. Those who are receiving systematic psychological treatment;
5. Those who have failed to respond to previous treatment with paroxetine or are allergic;
6. There is inflammation, scar or trauma at the site of operation, or other severe systemic infection.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HAMA Evaluation Questionnaire;HAMA Evaluation Questionnaire;Whoqol-bref Evaluation Questionnaire;